Cullen Capital Management LLC Sells 66,484 Shares of Johnson & Johnson $JNJ

Cullen Capital Management LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 6.0% in the third quarter, Holdings Channel reports. The firm owned 1,032,593 shares of the company’s stock after selling 66,484 shares during the period. Johnson & Johnson accounts for about 2.7% of Cullen Capital Management LLC’s investment portfolio, making the stock its 3rd largest position. Cullen Capital Management LLC’s holdings in Johnson & Johnson were worth $273,369,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of JNJ. Wellington Management Group LLP boosted its holdings in Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after buying an additional 2,513,321 shares during the last quarter. Deutsche Bank AG increased its stake in Johnson & Johnson by 8.5% during the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after buying an additional 1,225,676 shares in the last quarter. Fisher Asset Management LLC increased its stake in Johnson & Johnson by 11.5% during the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock worth $3,927,981,000 after buying an additional 1,530,070 shares in the last quarter. Amundi raised its holdings in shares of Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after acquiring an additional 2,001,139 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Johnson & Johnson by 1.9% during the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after acquiring an additional 148,497 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth Forminard sold 13,072 shares of the stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their position. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a research report on Thursday, October 15th. Argus set a $300.00 price target on Johnson & Johnson in a research note on Wednesday, July 29th. UBS Group set a $270.00 price target on Johnson & Johnson in a research report on Wednesday, October 14th. Morgan Stanley reduced their price objective on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. Finally, Weiss Ratings lowered Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $275.92.

Check Out Our Latest Report on Johnson & Johnson

Recent Johnson & Johnson Headlines

Investors following JNJ have been watching these headlines:

  • Positive Sentiment: J&J will pay $2.2 billion upfront for Ollin, with up to about $1.1 billion in additional regulatory and commercial milestone payments. The acquisition adds OLN324, a late-stage antibody being developed for wet age-related macular degeneration and diabetic macular edema, and could complement J&J’s existing eye-care business. J&J bets $2.2B on Ollin’s vision loss drug
  • Positive Sentiment: Blackstone Life Sciences will provide $750 million to fund OLN324’s Phase 3 program, helping support development of the drug while sharing its funding burden. Blackstone Life Sciences Announces $750 Million R&D Funding Agreement
  • Neutral Sentiment: OLN324 is still investigational, so its commercial prospects depend on successful trials, regulatory approval and uptake. The retinal-disease market is crowded and competitive, which could limit eventual returns on the acquisition. J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences

Johnson & Johnson Stock Performance

JNJ opened at $282.62 on Tuesday. Johnson & Johnson has a twelve month low of $195.90 and a twelve month high of $290.25. The firm has a market capitalization of $680.36 billion, a PE ratio of 42.82, a PEG ratio of 2.80 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The firm’s 50-day moving average price is $267.12 and its 200 day moving average price is $250.12.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. Johnson & Johnson’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is currently 81.21%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.